King's College London

Research portal

Inhaled corticosteroids for the treatment of COVID-19

Research output: Contribution to journalReview articlepeer-review

Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Peter J. Barnes, Alvar Agustí, Tobias Welte

Original languageEnglish
Article number220099
JournalEuropean Respiratory Review
Volume31
Issue number166
DOIs
Published31 Dec 2022

Bibliographical note

Funding Information: Support statement: Medical writing support, under the direction of the authors, was provided by Sharon Gill, PhD, CMC Connect, a division of IPG Health Medical Communications and was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines [109]. Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: © The authors 2022.

King's Authors

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454